Spotlight On... HHS taps Medidata for data to inform research into drug development costs; WuXi NextCODE picks up CAP accreditation; McKesson rolls out drug spend analysis tool; and more...

Medidata ($MDSO) has contributed data to an assessment of factors that drive up the cost of drug development. The resulting paper, which was coauthored by staffers at the Department of Health and Human Services (HHS), found clinical procedure costs were the top cost driver, adding evidence to the argument that the rising complexity of protocols has pushed up study budgets. Medidata provided data from repositories associated with its CRO contract and grant management offerings to support the research. Release

> WuXi NextCODE's Shanghai sequencing facility received accreditation from the College of American Pathologists. Release

> McKesson introduced a tool to assess the effect of changes in the prices of medicines. Item

> GenomeNext raised $1.2 million to advance its genomic data management and analysis platform. News

> Google's AI unit DeepMind unveiled plans to move into healthcare. Article

> ReelDx rolled out a video sharing platform to support communication with patients. More

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.